CDK4 and breast cancer: They demonstrated that short-term treatment of ER+ BC cell lines with the CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib led to alterations in many cellular pathways, including suppression of cell cycle signaling and changes in the DNA damage response.